Diabetes Breakthrough May Lead to New Treatment for Children and Adults
Wynnewood, PA, February 05, 2009 --(PR.com)-- A team of researchers from CureDM, Inc, in collaboration with the Lankenau Institute for Medical Research (LIMR) reported a ground breaking discovery with the potential to reverse type 1 and type 2 diabetes. In a paper published in Endocrine Practice, the leading peer-reviewed journal for practicing endocrinologists in the US and 65 countries, these researchers have described the discovery of a human peptide called the Human proIslet Peptide (HIP) that is responsible for regenerating insulin producing islets that may help reverse diabetes
From: Gr8discjck <gr8discjck@...>
To: nathanfaustmantrials@yahoogroups.com
Sent: Tuesday, January 27, 2009 1:42:45 PM
Subject: Re: [nathanfaustmantrials] Ask FDA to better serve the needs of diabetes patients
Hi Joshua.
I have a new one for you. Please take a look and advise.
Thanks for all your research analysis. Please see their latest news.
From: Joshua Levy <joshua2levy@ yahoo.com>
To: nathanfaustmantrial s@yahoogroups. com
Sent: Tuesday, January 6, 2009 11:27:33 AM
Subject: Re: [nathanfaustmantria ls] Ask FDA to better serve the needs of diabetes patients
I don't agree with your petition at all!
First, the letter only applies to medicines that treat type-2 diabetes, so it will not slow down a cure for type-1 at all.
Second, there have been a couple of drugs which actually got approved for type-2 diabetics which had bad side effects in terms of raising the chance of heart attacks. The FDA reacted to these problems by fixing their process: by requiring the drug companies to do testing focused specifically at heart risks. That is the right thing to do!
Prior to these new regulations, type-2 diabetic drugs could be approved after clinical trials lasting only 3-6 months. That's nuts! Those drugs are typically taken for years (maybe even decades). Requiring them to be tested for a year is long over due. The extra time is required to get a statistically valid sample of heart risk.
If we want a safe drug supply in this country, the FDA should go farther, and require post-approval (called "postmarket" ) safety testing lasting as long a the expected use of the drug. That is basic common sense. That would shake out a lot of safety issues before people got hurt, without slowing down drug approvals. But in the mean time, the FDA's rule change is a good step in the right direction. In my opinion.
Joshua Levy
From: Bernard Farrell <bernard.farrell@ gmail.com>
To: nathanfaustmantrial s@yahoogroups. com
Sent: Monday, January 5, 2009 8:15:01 PM
Subject: [nathanfaustmantria ls] Ask FDA to better serve the needs of diabetes patients
A large group of us has started an online petition to the FDA.
We're asking them to remove new requirements they recently placed on
diabetes drugs.
Please sign. The petition is at: http://HealTheFDA. com/
If you want more details, I've posted them on my blog at
http://is.gd/ eEMB.